Authors

Latest:

Dr Blakely on the Rationale for Investigating Neoadjuvant Osimertinib in EGFR-Mutated NSCLC

Collin Blakely, MD, PhD, discusses a phase 2 trial evaluating the use of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutated non-small cell lung cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

Spencer Feldman

Latest:

Aspirin Is Associated With Reduced Recurrence Risk in PI3K+ CRC

Aspirin reduced the risk of disease recurrence in colorectal cancer harboring PI3K pathway alterations.

Timothy M. Schmidt, MD

Latest:

Dr. Schmidt on the Promise of Bispecific Antibodies in Myeloma

Timothy M. Schmidt, MD, discusses the promise of bispecific antibodies in patients with multiple myeloma.

Julia S. Wong, MD,

Latest:

Dr Wong on Hypofractionation vs Conventional Fractionation in Breast Cancer Postmastectomy

Julia S. Wong, MD, discusses findings from data presented on patient-reported toxicity results from the randomized trial of fractionation following breast reconstruction in patients with breast cancer.

Amanda L. Jackson, MD

Latest:

Dr. Jackson on VEGF Versus PARP Inhibitors in Recurrent Ovarian Cancer

Amanda L. Jackson, MD, discusses choosing between VEGF inhibitors and PARP inhibitors in the treatment of patients with recurrent platinum-sensitive ovarian cancer.

Alexandra Stefanovic, MD

Latest:

Dr. Stefanovic on the Emergence of Umbralisib in MZL and Follicular Lymphoma

Alexandra Stefanovic, MD, discusses the emergence of umbralisib in marginal zone lymphoma and follicular lymphoma.

Jue Wang, MD

Latest:

Dr Wang on Testing for Molecular Alterations in Relapsed/Refractory Urothelial Carcinoma

Jue Wang, MD, discusses how to approach testing for molecular alterations in patients with relapsed or refractory urothelial carcinoma.

Ricardo D. Parrondo, MD

Latest:

Clinical Pearls and Impacts to Practice from EHA 2024

The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.

Chris Ryan

Chris Ryan joined

Latest:

China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma

China’s NMPA approved isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.

Tiffany S. Lai, MD

Latest:

Dr. Lai on the Role of Maintenance Therapy and Secondary Cytoreduction in Ovarian Cancer

Tiffany S. Lai, MD, discusses the role of maintenance therapy and secondary cytoreduction in ovarian cancer.

Anne Runyon

Latest:

Oncology Providers Face Rising Pressures From Payers Over Therapy Choices

Insurance companies are beginning to indirectly manage prescribing to better manage costs.

Christopher Lieu, MD, Anschutz Medical Campus

Latest:

ASCO GI 2021: MRD Detection With ctDNA From Assays

Expert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.

UT Southwestern

Latest:

Experimental Drug Could Spur Immunotherapy Response in Patients With Non–Small Cell Lung Cancer

Research led by UT Southwestern scientists suggests that an investigational drug could restore the ability of some non–small cell lung cancers to respond to an immune checkpoint blockade, a therapy that harnesses the immune system to fight malignant tumors.

Danny Nguyen, MD

Latest:

Dr. Nguyen on Managing Mobocertinib-Related GI Toxicities in EGFR Exon 20 Insertion+ NSCLC

Danny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.

Shahrzad A. Zamani

Latest:

Zamani on Disparities in Cancer Care Among Patients of Sexual/Gender Minority

Shahrzad A. Zamani, discusses the prevalence of cancer disparities in patients with cancer in sexual and gender minority populations.

Amila Patel, PharmD, BCOP

Latest:

Digital Health and Process Improvements Enhance Community-Based Patient Care

A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.

Samuel K. Caughron, MD, FCAP

Latest:

Role of a Pharmacist in Developing Treatment Pathways and Educating Patients

Ryan Haumschild, PharmD, MS, MBA, reflects on how oncologic pharmacists can help to develop treatment pathways and educate patients on precision medicine.

Nadia Nocera Zachariah, MD

Latest:

Unmet Needs in the Treatment of HR+/HER2- Breast Cancer

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.

Andrew McKenzie, PhD

Latest:

Dr McKenzie on Updates to ASCO Treatment Guidelines in Metastatic Breast Cancer

Andrew McKenzie, PhD, discusses the updates to the ASCO clinical practice guidelines for biomarker testing in patients with metastatic breast cancer.

Linda Vahdat, MD, MBA

Latest:

Dr Vahdat on the Role of Copper Depletion in Reducing Metastatic Disease Risk in TNBC

Linda Vahdat, MD, MBA, discusses the role of copper depletion in reducing the risk of metastatic disease development in triple-negative breast cancer.